Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study

Table 1 Time to resolution of all influenza-like symptoms between treatment groups

Group for analysis	Hazard ratio (HR)	95 % CI	P-value
Age Group: <50 and BMI <30	*1.307*	*1.010–1.691*	*0.018*
Age Group: <50 and BMI ≥30	0.782	0.429–1.426	0.370
Age Group: ≥50 and BMI <30	0.838	0.534–1.316	0.383
Age Group: ≥50 and BMI ≥30	0.879	0.445–1.736	0.683
Age Group: <50 and resolution of symptoms to "mild" or "none"	*1.298*	*1.035–1.627*	*0.009*

ISSN: 1471-2334